Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022
Abstract Background The Food and Drug Administration (FDA)’s Accelerated Approval (AA) pathway has increasingly used to authorize market approval of new drugs amid controversy. The present study aims to inform the most recent data on the strength of clinical evidence supporting such approvals. Metho...
Saved in:
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | BMC Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12916-024-03800-6 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846112526593425408 |
|---|---|
| author | Xiaofang Zhang Carl C. Peck Yaning Wang Thomas D. Szucs Wan Sun Xue Bai Siyu Chen Fengzhi Wang Yangfeng Wu |
| author_facet | Xiaofang Zhang Carl C. Peck Yaning Wang Thomas D. Szucs Wan Sun Xue Bai Siyu Chen Fengzhi Wang Yangfeng Wu |
| author_sort | Xiaofang Zhang |
| collection | DOAJ |
| description | Abstract Background The Food and Drug Administration (FDA)’s Accelerated Approval (AA) pathway has increasingly used to authorize market approval of new drugs amid controversy. The present study aims to inform the most recent data on the strength of clinical evidence supporting such approvals. Methods Evidentiary characteristics of pre-approval pivotal clinical studies and regulator-required post-approval confirmatory studies supporting AAs between 2015 and 2022 were extracted from publicly available FDA documents. Descriptive analyses were conducted for each of the characteristic including study design, study phase, primary endpoint, number of participants, and magnitude of effect. Trends of these characteristics over time were documented and accounted for class of drugs, application type, novelty, orphan status, and oncology/non-oncology indications. Results During 2015–2022, 156 drug-indication pairs received AA. To support these AAs, 77% of pre-approval pivotal trials employed single-arm designs, and 22% were phase I trials, with a median of 92 participants (IQR, 45–125); 61% of post-approval confirmatory studies were required by FDA to use randomized controlled design, 25% to use clinical endpoints, and 33% specified the number of participants requirement. During the 8-year observation period, the pairs approved via AA pathway almost tripled from 20 (2015–2016) to 59 (2019–2020) and fell to 36 (2021–2022); the corresponding proportion to all new drug approvals showed the same trend. Single-arm pre-approval pivotal studies increased from 55% (2015–2016) to 91% (2019–2020) and fell to 69% (2021–2022), while the median number of participants decreased from 106 (2015–2016) to 59 (2019–2020) and rose to 106 (2021–2022). Randomized controlled post-approval confirmatory studies decreased from 75% (2015–2016) to 42% (2019–2020) and rebounded to 75% (2021–2022), while those using surrogate endpoints increased from 50% (2015–2016) to 72% (2021–2022). Analyses adjusting for drug class, application type, novelty, orphan status, and oncology/non-oncology showed similar results. Conclusions The number of drug-indication pairs receiving AA increased sharply during 2015–2016 to 2019–2020 but fell in 2021–2022. Meanwhile, the strength of clinical evidence supporting FDA’s AAs appeared to decline from 2015 to 2020 but seems to have improved in 2021–2022. Measures should be taken to further improve the strength of evidence in Accelerated Approvals. |
| format | Article |
| id | doaj-art-ee57e2e5d81a4c5eb044bbe86c74f0cc |
| institution | Kabale University |
| issn | 1741-7015 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | BMC Medicine |
| spelling | doaj-art-ee57e2e5d81a4c5eb044bbe86c74f0cc2024-12-22T12:30:31ZengBMCBMC Medicine1741-70152024-12-0122111510.1186/s12916-024-03800-6Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022Xiaofang Zhang0Carl C. Peck1Yaning Wang2Thomas D. Szucs3Wan Sun4Xue Bai5Siyu Chen6Fengzhi Wang7Yangfeng Wu8Peking University First HospitalDepartment of Bioengineering and Therapeutic Sciences, University of CaliforniaWuhan Createrna Science and Technology Co., Ltd.European Center of Pharmaceutical Medicine, University of BaselNational Biotech Group Clinical and Regulatory Sciences Joint Laboratory, Peking University Health Science- ChinaNational Biotech Group Clinical and Regulatory Sciences Joint Laboratory, Peking University Health Science- ChinaPeking University First HospitalNational Biotech Group Clinical and Regulatory Sciences Joint Laboratory, Peking University Health Science- ChinaClinical Research Institute, Institute of Advanced Clinical Medicine, Peking UniversityAbstract Background The Food and Drug Administration (FDA)’s Accelerated Approval (AA) pathway has increasingly used to authorize market approval of new drugs amid controversy. The present study aims to inform the most recent data on the strength of clinical evidence supporting such approvals. Methods Evidentiary characteristics of pre-approval pivotal clinical studies and regulator-required post-approval confirmatory studies supporting AAs between 2015 and 2022 were extracted from publicly available FDA documents. Descriptive analyses were conducted for each of the characteristic including study design, study phase, primary endpoint, number of participants, and magnitude of effect. Trends of these characteristics over time were documented and accounted for class of drugs, application type, novelty, orphan status, and oncology/non-oncology indications. Results During 2015–2022, 156 drug-indication pairs received AA. To support these AAs, 77% of pre-approval pivotal trials employed single-arm designs, and 22% were phase I trials, with a median of 92 participants (IQR, 45–125); 61% of post-approval confirmatory studies were required by FDA to use randomized controlled design, 25% to use clinical endpoints, and 33% specified the number of participants requirement. During the 8-year observation period, the pairs approved via AA pathway almost tripled from 20 (2015–2016) to 59 (2019–2020) and fell to 36 (2021–2022); the corresponding proportion to all new drug approvals showed the same trend. Single-arm pre-approval pivotal studies increased from 55% (2015–2016) to 91% (2019–2020) and fell to 69% (2021–2022), while the median number of participants decreased from 106 (2015–2016) to 59 (2019–2020) and rose to 106 (2021–2022). Randomized controlled post-approval confirmatory studies decreased from 75% (2015–2016) to 42% (2019–2020) and rebounded to 75% (2021–2022), while those using surrogate endpoints increased from 50% (2015–2016) to 72% (2021–2022). Analyses adjusting for drug class, application type, novelty, orphan status, and oncology/non-oncology showed similar results. Conclusions The number of drug-indication pairs receiving AA increased sharply during 2015–2016 to 2019–2020 but fell in 2021–2022. Meanwhile, the strength of clinical evidence supporting FDA’s AAs appeared to decline from 2015 to 2020 but seems to have improved in 2021–2022. Measures should be taken to further improve the strength of evidence in Accelerated Approvals.https://doi.org/10.1186/s12916-024-03800-6Accelerated approvalStrength of clinical evidenceTrend over timeRegulatory science |
| spellingShingle | Xiaofang Zhang Carl C. Peck Yaning Wang Thomas D. Szucs Wan Sun Xue Bai Siyu Chen Fengzhi Wang Yangfeng Wu Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 BMC Medicine Accelerated approval Strength of clinical evidence Trend over time Regulatory science |
| title | Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 |
| title_full | Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 |
| title_fullStr | Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 |
| title_full_unstemmed | Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 |
| title_short | Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022 |
| title_sort | strength of clinical evidence supporting the united states food and drug administration accelerated approvals from 2015 to 2022 |
| topic | Accelerated approval Strength of clinical evidence Trend over time Regulatory science |
| url | https://doi.org/10.1186/s12916-024-03800-6 |
| work_keys_str_mv | AT xiaofangzhang strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT carlcpeck strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT yaningwang strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT thomasdszucs strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT wansun strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT xuebai strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT siyuchen strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT fengzhiwang strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 AT yangfengwu strengthofclinicalevidencesupportingtheunitedstatesfoodanddrugadministrationacceleratedapprovalsfrom2015to2022 |